| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 144.08 KB | Adobe PDF |
Orientador(es)
Resumo(s)
One of the consequences of the metabolic progression of diabetes is kidney disease, being also a main cause of diabetes related morbidity and mortality. Therefore, earlier adoption of methods to estimate chronic kidney disease risks along with a more accurate glycemic index for patients with type 2 diabetes mellitus is highly desirable. One of the widely used tubular injury markers is N-acetyl-β-D-glucosaminidase (NAG), a lysosomal enzyme of renal proximal tubular epithelial cells. One study demonstrated that the association between glycated albumin (GA) and uNAG excretion and observed that GA was significantly associated with uNAG excretion independent of other confounding factors. Consequently, this study suggest that GA can be a strong independent predictor of early renal tubular damage, beyond its role as a surrogate marker of glucose control (Huh et al., 2018).
Descrição
Palavras-chave
Type 2 diabetes mellitus Early diagnosis Glycated albumin
Contexto Educativo
Citação
Ribeiro, A. R., Luis, C., Baylina, P., & Fernandes, R. (2019). Glycated Albumin: A new biomarker for monitoring metabolic progression of diabetes. Workshop on R&D Projects: Proceedings, 18–19.